@medsir.bsky.social
Bring your idea to life💡Creating successful IITs & optimal drug development📊Medica Scientia Innovation Research🇪🇸🇺🇸 www.medsir.org
📢 New publication in Nature Medicine! The phase 2 #ATRACTIB trial tested atezolizumab + paclitaxel + bevacizumab as 1L for advanced TNBC, regardless of PD-L1 status.
🕒 Median PFS: 11 months
🎯 ORR: 63%
🔗 Read the full article here 👉🏼
www.nature.com/articles/s41...
#BreastCancer
We leave #ASCO25 with full hearts and minds brimming with science. Presenting #TUXEDO3, sharing #ADELA & #WINB, and connecting with passionate people—this is what drives us. Thank you all. We take home more than results. Time to rest… until next time!
03.06.2025 18:25 — 👍 0 🔁 0 💬 0 📌 0
Funded by Debiopharm & Gilead, #WINBtrial combines sacituzumab/govitecan with a WEE1 inhibitor to increase DNA damage in tumor cells. It also explores biomarkers to predict who benefits most.
🎥 Watch the interview 👇🏼
www.youtube.com/watch?v=CKas...
#MEDSIRatASCO
Dr. Tim Robinson breaks down the #WINBtrial, a study aiming to boost the effectiveness of sacituzumab/govitecan in breast cancer (TNBC & HR+). Despite its promise, many patients don't respond or progress quickly.
Dr. María Gion presented #WINBtrial results, a phase Ib/II trial in pretreated HR+/HER2- & TNBC.
📌Sacituzumab govitecan + Debio 0123, a selective, brain-penetrant WEE1 inhibitor.
💡Phase Ib sets dose for phase II, aiming tumor regression.
🇪🇸 ¡Día 4 en #ASCO25!
Isabel Tundidor nos cuenta cómo vivimos estas jornadas intensas pero muy gratificantes: ciencia, colaboración y mucha energía.
#MEDSIRatASCO
Day 4!
Isabel Tundidor shares how we combine hard work, science & collaboration during these intense (but rewarding) days.
👉🏼 www.youtube.com/shorts/Qxsac...
#ASCO25 #MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
🇪🇸 Hoy presentamos los pósters de #ADELAtrial y #WINBtrial en Hall A, de 9:00 a 12:00 (GMT-5).
📍 WINB: #479b
📍 ADELA: #103b
#GoodMorning MEDSIR
Today we're presenting the posters for #ADELAtrial and #WINBtrial in Hall A, from 9:00 to 12:00 (GMT-5).
📍 WINB: #479b
📍 ADELA: #103b
👉🏼 medsir.org/events/asco2...
#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
🇪🇸 Carmen Mora, del equipo de BD de #MEDSIR, nos actualiza desde el día 2 en #ASCO25. Reuniones clave, colaboraciones globales y ciencia en acción.
¡Seguimos!
#MEDSIRatASCO
Carmen Mora, from BD team, shares updates from day 2 at #ASCO25. Key meetings, global collaborations, and science in action. Let’s keep it going! 🚀
👉🏼 www.youtube.com/shorts/jcVK6...
#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
Dr. Matthias Preusser will also co-chair our exclusive event during #ESMO25:
🧠 #MEDTALK: "Exploring the Future of Theranostics"
📅 Oct 19 | 🕖 7:00 PM | 📍 Berlin
🚨 Limited spots — request yours now: www.medsir.org/events/medtalk
#MEDSIRatASCO
On Day 1 of #ASCO25, one of the highlights for #MEDSIR was without a doubt the oral presentation of #TUXEDO3trial, exploring patritumab deruxtecan (HER3-DXd) in patients with very limited treatment options.
🎥 Watch Dr. Preusser explain more 👇
www.youtube.com/watch?v=bjyy...
🇪🇸 Día 2 en #ASCO25 y empezamos con lo que más nos inspira: equipo, planificación y propósito. Reuniones, conexiones y nuevas oportunidades nos esperan. ¡Vamos con todo! 🚀
👉🏼 Sigue nuestra actividad en #ASCO aquí: lnkd.in/dkDs-bp4
#GoodMorning MEDSIR!
Day 2 at #ASCO25 kicks off with what drives us most: teamwork, planning, and purpose. Meetings, connections, and new opportunities await. Let’s go! 🚀
👉🏼 Stay tuned: lnkd.in/dkDs-bp4
#MEDSIRatASCO #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
🇪🇸 ¿Ya le echaste un vistazo a nuestra newsletter exclusiva desde #ASCO?
👉 Invitado especial: Dr. Matthias Preusser
🗣️ Nos habla sobre #TUXEDO3trial, presentado en ASCO y publicado en Nature Medicine.
👉🏼 Haz clic aquí y no te la pierdas: www.linkedin.com/pulse/10-yea...
#MEDSIRatASCO
Have you seen our exclusive newsletter from #ASCO25?
👉 Special Guest: Dr. Matthias Preusser
🗣️ Talking about #TUXEDO3trial, presented at
@ascocancer.bsky.social and published in Nature Medicine.
👉🏼 Click here and don’t miss it: www.linkedin.com/pulse/10-yea...
This study, addressing a major unmet need, is now published in Nature Medicine! 🧠📄
👉 Watch the presentation: medsir.org/_files/ugd/3...
👉 Read the press release: medsir.org/post/new-pot...
#MEDSIRLive @ascocancer.bsky.social #MedicalResearch #CancerCare #Innovation
#MEDSIRatASCO
Major milestone at #ASCO25!
We presented the #TUXEDO3trial led by Dr. Matthias Preusser with Universität Wien as an oral presentation. The Phase II trial tested HER3-DXd in patients with brain mets & leptomeningeal disease.
Bring Your Research Ideas to Life — Meet with MEDSIR @wearemedsir at #ASCO25 to Get Started! 👉 buff.ly/BHKdQ7I
MEDSIR, a global oncology research company that designs & runs innovative, patient-focused clinical trials. Book a meeting at ASCO & explore how you can work together & advance your ideas
🇪🇸 Nuestro BD Manager, Aurelio del Pino, habla en
@ascocancer.bsky.social sobre alianzas clave y más investigación clínica.
💬 Dale al play y acompáñanos: medsir.org/events/asco2...
#MEDSIRatASCO
Our BD Manager, Aurelio del Pino, shares how we're expanding at #ASCO25, connecting with key players & forging new partnerships to drive clinical research.
💬 Hit play & join us: medsir.org/events/asco2...
#MEDSIRLive #MedicalResearch #CancerCare #Innovation
@ascocancer.bsky.social
🇪🇸 Las sesiones educativas ya están en marcha y nuestro equipo ya está en Chicago. ¿Quieres reunirte con nosotros en #ASCO25? Agenda tu cita aquí 👉 medsir.org/events/asco2...
30.05.2025 18:38 — 👍 1 🔁 0 💬 0 📌 0#MEDSIRatASCO
Educational sessions are underway and our team is already in Chicago! Want to meet with us at #ASCO25? Schedule your meeting here 👉 medsir.org/events/asco2...
#MEDSIRLive #ASCO25 #MedicalResearch #CancerCare #Innovation @ascocancer.bsky.social
🇪🇸 Gran día para #MEDSIR con la presentación oral de nuestro estudio #TUXEDO3trial.
🕒 16:21–16:33
👨⚕️ Dr. Matthias Preusser
📍 S100bc | Sesión Tumores del Sistema Nervioso Central
Conéctate con nosotros en Chicago: medsir.org/events/asco2...
#GoodMorning MEDSIR! Big day ahead with the oral presentation of our study #TUXEDO3trial
🕒 4:21–4:33 PM CDT
👨⚕️ Dr. Matthias Preusser
📍 S100bc | CNS Tumors Session
Let’s connect in Chicago: medsir.org/events/asco2...
#MEDSIRLive #ASCO25 #MedicalResearch #CancerCare #Innovation
🇪🇸 ¡Hoy arranca @ascocancer.bsky.social 2025! Os iremos contando todo lo relacionado con nuestra participación en el congreso oncológico más importante del año.
¡Estad atentos!
#MEDSIRatASCO
@ascocancer.bsky.social 2025 kicks off today! We'll be sharing updates on #MEDSIR's participation in the most important oncology congress of the year.
Stay tuned! 👀
#MEDSIRLive #ASCO25 #MedicalResearch #CancerCare #Innovation
🇪🇸 Nos preparamos para #ASCO y nuestro Scientific Impact Manager, José Rodríguez Morató, tiene un mensaje para ti.
¿Nos vemos en Chicago?
#MEDSIRatASCO is almost here!
Our Scientific Impact Manager, Jose Rodríguez Morató, has a quick message for you.
Let’s connect in Chicago and talk science!
More on our #ASCO25 plans 👉🏼 www.medsir.org/events/asco2...
#ASCO25 #MedicalResearch #CancerCare #Innovation
